By Simon Hua, Chairman, BioMetas (Special Guest Contributor)
One of the most valuable perspectives we can share with the RESI community comes directly from the organizations that choose to invest in early stage innovation. At RESI JPM 2026, Title Sponsor BioMetas took part across partnering, project discussions, and collaboration with emerging biotech companies and investors, offering a clear view into how sponsors engage within the RESI ecosystem.
As Life Science Nation looks ahead to upcoming RESI conferences in 2026, sponsorship continues to be an opportunity for organizations to connect early with innovative companies, participate in targeted partnering, and build relationships that extend well beyond the conference itself. To learn more about RESI sponsorship opportunities, please contact us at resi@lifesciencenation.com
Below is BioMetas’ reflection on their experience at RESI JPM 2026, originally published on LinkedIn.
BioMetas Attends RESI JPM 2026, Focusing on Early Innovation and Industry Collaboration
RESI JPM 2026 was held in San Francisco on January 12–13, with additional online one-to-one partnering sessions on January 14 and January 19–20. As a key investment and business-matching platform during J.P. Morgan Healthcare Conference (JPM) week, the conference focuses on early- and growth-stage life science projects, bringing together biotech companies, investors, and industry partners from around the world. As a Title Sponsor, BioMetas participated deeply in the overall conference ecosystem. Leveraging its one-stop CRO platform and innovative incubation and investment model, BioMetas engaged in targeted discussions with international biotech companies and investment institutions around the core needs of early-stage innovation projects, including R&D efficiency, capital structure optimization, and industry resource alignment, exploring diversified pathways for R&D collaboration and industry co-development.
The conference centered on highly targeted one-to-one partnering meetings, complemented by investor roundtables, innovation project pitch and selection sessions, and multiple themed workshops. Topics spanned drug development, medical devices, diagnostics, and digital health, forming a multidimensional engagement framework of “project showcase – capital connection – industry collaboration,” enabling innovative projects to build high-quality connections with potential investors and partners within a short timeframe.
During the conference, BioMetas focused on the practical needs of early-stage projects across critical preclinical stages, including protein and antibody production, in vitro and in vivo efficacy studies, tumor and immunology-related disease model development, and DMPK. BioMetas discussed project advancement strategies in depth with multiple innovative companies. With an integrated technical system covering target validation, molecular and cellular functional studies, animal efficacy testing, and PK/safety evaluation, BioMetas provides scalable, IND-enabling, end-to-end R&D support for innovative projects across different technological approaches.
In parallel, based on its EFS (Equity for Service) collaboration model, BioMetas explored more forward-looking partnership mechanisms with selected projects from seed stage to rapid growth stage. By exchanging part of the services for a small equity stake, combined with necessary cash investment, BioMetas helps early teams initiate R&D quickly while keeping financial pressure manageable, and achieve key milestones that build a stronger technical foundation for subsequent financing, licensing, or M&A. In today’s more rational capital environment, where efficiency and data quality are increasingly emphasized, a collaborative model integrating “services + capital + industry resources” is becoming an important accelerator for early-stage projects.
RESI JPM 2026 was not only a stage for showcasing innovation, but also an efficient collaboration platform connecting technology, capital, and industry resources. Through its precise one-to-one partnering mechanism, the conference significantly improved communication efficiency, enabling companies at different stages to access more targeted collaboration opportunities within limited time.
Through this participation, BioMetas further strengthened its dual role in the global innovation ecosystem: on one hand, providing reliable and scalable R&D support to global clients; on the other hand, actively engaging in early value co-creation and pursuing earlier-stage, deeper collaborations with high-quality projects.
Looking ahead, BioMetas will continue to expand collaboration with global biotech companies, investors, and industry partners through international conferences and industry networks, accelerating the translation and industrialization of innovative research outcomes and therapeutic programs, and contributing stronger technical and collaborative support to the global biopharmaceutical innovation ecosystem.
About RESI
Through its RESI partnering events and global collaboration programs, Life Science Nation connects entrepreneurs with global investors and strategic partners, accelerating financing for early-stage life science companies.
About BioMetas
BioMetas is a globally leading one-stop CRO platform for innovative drug R&D, bringing together top domestic CRO resources and an international, highly experienced technical team. With efficient and innovative expertise, rigorous scientific standards, and a comprehensive quality management system, BioMetas provides compliant, high-quality, and customized end-to-end preclinical R&D solutions. Its services cover the full process from drug discovery to IND for both small-molecule drugs and biologics.
| Register for RESI Europe |
Next Phase Newsletter 
Leave a comment